RXi Pharmaceuticals Corp (RXII)

0.61
0.00 (0.00)
NASDAQ : Health Care
Prev Close 0.61
Open 0.60
Day Low/High 0.58 / 0.62
52 Wk Low/High 1.26 / 6.49
Volume 52.45K
Avg Volume 335.70K
Exchange NASDAQ
Shares Outstanding 23.25M
Market Cap 14.41M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

RXi Pharmaceuticals Announces The Initiation Of Its Consumer Testing Program With RXI-231

RXI-231 is in development as a cosmetic ingredient that may improve the appearance of uneven skin tone and pigmentation

RXi Pharmaceuticals Corporation Selected To Present At The Cavendish Global Health Impact Forum

Forum brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

RXi Pharmaceuticals Granted Patent In Japan For Lead Clinical Candidate RXI-109

RXI-109 is a self-delivering RNAi compound (sd-rxRNA) in development to reduce dermal and ocular fibrosis

RXi Pharmaceuticals To Present At The 5th Annual Cancer BioPartnering & Investment Forum

Focusing on Advances in Immuno-Oncology

RXi Pharmaceuticals To Present At Leading Investor And Healthcare Conferences

19th Annual BIO CEO & Investor Conference and 2nd Annual Disruptive Growth & Healthcare Conference

RXi Pharmaceuticals Completes Acquisition Of MirImmune Inc. And Appoints New Chief Business Officer

RXi Pharmaceuticals Completes Acquisition Of MirImmune Inc. And Appoints New Chief Business Officer

Acquisition expands RXi's pipeline to include cell-based immunotherapy to treat cancer

RXi Pharmaceuticals Enters Into Exclusive Option Agreement To Acquire MirImmune Inc.

RXi Pharmaceuticals Enters Into Exclusive Option Agreement To Acquire MirImmune Inc.

Acquisition will broaden RXi's pipeline to include immuno-oncology with the use of the Company's proprietary sd-rxRNA® platform